SecBot SecBot
SECBOTREPLAY Home › Report › IMNM

IMNM · Immunome filed an automatic shelf registration statement (S-3ASR) to…

Immunome Inc. · S-3ASR filed Nov 9, 2026 at 16:56 ET

At the news

NEUTRALIMPACT 3/10

S-3ASR filed Nov 9, 2026 at 16:56 ET

Immunome filed an automatic shelf registration statement (S-3ASR) to register 4,425,487 shares of common stock for resale by Bristol-Myers Squibb Company (BMS). These shares were issued to BMS on October 2, 2026, as part of the consideration to terminate all milestone and royalty obligations under the varegacestat license agreement. Immunome will not receive any proceeds from the resale. The filing is a routine registration obligation, not a new capital raise.

  • Registration covers 4,425,487 shares of common stock for resale by BMS.
  • Shares were issued to BMS on October 2, 2026, as consideration for Amendment No. 4 to the License Agreement.
  • Immunome paid BMS $20.0 million in cash and issued the shares to eliminate all future milestone and royalty obligations under the varegacestat license.
  • Immunome will not receive any proceeds from the resale of these shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access